Principal Investigator

Sylvain Meloche

Signalling and Cell Growth

Subscribe to the newsletter

After obtaining his Ph.D. in Molecular Pharmacology at the Université de Montréal, in 1988, Sylvain Meloche completed postdoctoral training in immunology at the Montreal Clinical Research Institute, followed by additional postdoctoral training in biochemistry at the Université de Nice, in France.

He began his teaching career in 1992 and established his research activities at the Centre hospitalier de l’Université de Montréal. Principal Investigator in the Signalling and Cell Growth Research Unit, he joined IRIC in 2003. Sylvain Meloche is a Professor in the Department of Pharmacology and Physiology of the Faculty of Medicine at the Université de Montréal.

Principal Investigator, Signalling and Cell Growth Research Unit
High-Throughput Screening Core Facility Scientific direction

Professor, Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal

Research unit on signalling and cell growth

Marcelle-Coutu Pavilion, 2306-5

Phone (office)
(514) 343-6966
Fax
(514) 343-7780
Email
sylvain.meloche@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Signalling and Cell Growth

Sylvain Meloche and his team study the signalling mechanisms that control cell division, the differentiation and survival of normal and cancer cells. The research aims to identify novel therapeutic targets for cancer treatment based on these mechanisms.

Discover the research unit View the research team

Research topics

Publications

  • July 25, 2024

    Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.

    Voisin L, Lapouge M, Saba-El-Leil MK, Gombos M, Javary J, Trinh VQ, Meloche S
    Dis Model Mech 2024-07-25 ;17( 7 ):

  • July 10, 2024

    Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.

    Tambay V, Raymond VA, Voisin L, Meloche S, Bilodeau M
    Int J Mol Sci 2024-07-10 ;25( 14 ):

  • June 1, 2024

    ERK3 is involved in regulating cardiac fibroblast function.

    Sahadevan P, Dingar D, Nawaito SA, Nair RS, Trépanier J, Sahmi F, Shi Y, Gillis MA, Sirois MG, Meloche S, Tardif JC, Allen BG
    Physiol Rep 2024-06-01 ;12( 11 ):e16108

  • March 5, 2024

    OSGN-1 is a conserved flavin-containing monooxygenase required to stabilize the intercellular bridge in late cytokinesis.

    Goupil E, Lacroix L, Brière J, Guga S, Saba-El-Leil MK, Meloche S, Labbé J
    Proc Natl Acad Sci U S A 2024-03-05 ;121( 11 ):e2308570121

  • See all publications

News

  • October 31, 2023

    A CRS grant to validate therapeutic targets in liver cancer

    The team led by Sylvain Meloche, Director of IRIC’s Signaling and Cell Growth Research Unit, has been awarded a two-year grant of $125,000 for the project “Advanced preclinical validation of SRC-family kinases as therapeutic targets in liver cancer”. This grant is funded in partnership with the Canadian Liver Foundation.

  • See all news

Awards and distinctions

  • Project Grant - Canadian Institutes of Health Research, 2021

  • Canada Research Chair (tier 1) in Cellular Signaling, 2011-2018

  • Canada Research Chair (tier 1) in Cellular Signaling, 2004-2011

  • Biotechnology of Tomorrow Award, Genesis Awards, 2009

  • National Investigator, The Fonds de recherche du Québec – Santé, 2003-2004

  • Scientist, Medical Research Council of Canada, 1998-2003

  • Joe Doupe Young Investigator Award, Canadian Society for Clinical Investigation, 1995

  • Scholar, Medical Research Council of Canada, 1992-1997

    • See all awards